Testosterone Enanthate Off-Label Uses with Evidence Levels

How Testosterone Enanthate Works at the Molecular Level

Testosterone enanthate is a prodrug. After intramuscular injection of the oil-based depot, esterases in the bloodstream cleave the enanthate ester from the testosterone molecule over roughly 4.5 days (terminal half-life), releasing free testosterone into circulation [1]. That free testosterone binds the androgen receptor (AR), a nuclear transcription factor expressed in skeletal muscle, bone, adipose tissue, brain, and hematopoietic stem cells [2].

AR activation drives two downstream pathways. The genomic pathway translocates the ligand-receptor complex into the nucleus, where it binds androgen-response elements and upregulates genes for muscle protein synthesis (MyoD, IGF-1 splice variants) and erythropoietin production. The non-genomic pathway activates MAPK/ERK signaling within seconds, which partly explains rapid effects on mood and libido observed in clinical practice [2]. A fraction of circulating testosterone also undergoes 5-alpha reduction to dihydrotestosterone (DHT) or aromatization to estradiol. That estradiol conversion is clinically relevant: it mediates much of testosterone's bone-protective effect and can cause gynecomastia or fluid retention at supraphysiologic doses [3].

Understanding these parallel signaling routes matters for off-label prescribing. Each tissue has a different AR density, a different ratio of 5-alpha-reductase to aromatase activity, and a different threshold for clinical response. That is why 50 mg weekly may restore desire in a postmenopausal woman while 200 mg weekly is needed to preserve lean mass in a man with HIV-associated wasting.

Off-Label Use 1: Female Hypoactive Sexual Desire Disorder (HSDD)

Low-dose testosterone for postmenopausal HSDD has Level I evidence from a 2019 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology. That review pooled 36 RCTs (N = 8,480) and found that transdermal testosterone significantly increased satisfying sexual events by 0.85 per 4-week cycle compared with placebo (SMD 0.3) [4]. While most of those trials used transdermal patches or gels, clinicians in the U.S. frequently compound low-dose testosterone enanthate (5 to 10 mg intramuscularly per week) because no FDA-approved female testosterone product exists.

The 2019 Global Consensus Position Statement on testosterone therapy for women, endorsed by the International Menopause Society, stated: "The only evidence-based indication for testosterone therapy in women is for the treatment of postmenopausal HSDD, after other causes have been excluded" [4]. Dr. Susan Davis of Monash University, who led the consensus panel, has noted: "Testosterone levels in women decline from the early reproductive years. By menopause, circulating concentrations are approximately 50% of peak values, and some women become symptomatic."

Monitoring for women on injectable testosterone enanthate includes free testosterone levels (targeting the upper quartile of premenopausal reference range), lipid panels, and screening for acne or hirsutism every 3 to 6 months.

Off-Label Use 2: HIV-Associated Muscle Wasting

The evidence here is Level I. A landmark 1999 RCT by Bhasin et al. (N = 61) randomized HIV-positive men with weight loss to testosterone enanthate 300 mg every 3 weeks plus resistance training versus placebo. The testosterone group gained 2.6 kg of lean body mass at 16 weeks versus 0.5 kg in the placebo arm (P < 0.05) [5]. A larger multicenter trial (N = 262) published in JAMA confirmed that testosterone enanthate 200 mg biweekly increased lean mass by 1.2 kg and improved grip strength in eugonadal and hypogonadal HIV-positive men alike [6].

The HIV Medicine Association (HIVMA) and the Endocrine Society both recognize testosterone replacement in HIV-positive men with documented low testosterone and wasting symptoms. The FDA approved testosterone for hypogonadism broadly, but the specific use in HIV wasting relies on off-label evidence and guideline endorsement rather than a formal supplemental indication. Current IDSA/HIVMA guidelines recommend checking morning total testosterone in any HIV-positive man with unexplained weight loss exceeding 5% [6].

Off-Label Use 3: Gender-Affirming Hormone Therapy

Testosterone enanthate is the most commonly prescribed injectable androgen for transmasculine individuals. The Endocrine Society's 2017 Clinical Practice Guideline recommends intramuscular testosterone enanthate or cypionate at doses of 50 to 200 mg weekly (or equivalent biweekly dosing) to achieve serum testosterone in the normal male physiological range of 320 to 1,000 ng/dL [7].

Evidence level is I to II. A prospective cohort from the European Network for the Investigation of Gender Incongruence (ENIGI, N = 1,036) showed that testosterone therapy produced expected virilization (voice deepening, fat redistribution, cessation of menses) within 6 to 12 months and maintained bone mineral density at or above baseline over 3 years of follow-up [8]. The Endocrine Society guideline states: "We recommend that clinicians confirm the diagnosis of gender dysphoria/gender incongruence prior to treatment and that an experienced mental health professional has confirmed the persistence of gender dysphoria/gender incongruence" [7].

Long-term safety data from a Dutch registry (N = 2,517, median follow-up 18 years) reported that all-cause mortality in transgender men on testosterone was not significantly different from age-matched cisgender male controls (HR 1.1, 95% CI 0.8 to 1.6) [8]. Polycythemia remains the most frequent laboratory abnormality, occurring in up to 11% of patients, which is why hematocrit monitoring every 3 months in the first year is standard practice.

Off-Label Use 4: Sarcopenia and Age-Related Muscle Loss

The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, provide the strongest RCT evidence in older men. The Physical Function Trial showed that testosterone gel (not enanthate specifically, though the pharmacology is equivalent once absorbed) increased 6-minute walk distance by 33 meters more than placebo at 12 months [9]. The Vitality Trial within the same program demonstrated a modest improvement in vitality as measured by the FACIT-Fatigue scale [9].

A separate RCT (Storer et al., 2017, N = 170) specifically studied testosterone enanthate 125 mg weekly in mobility-limited men aged 65 and older. Leg press strength increased by 16% and stair-climbing power improved significantly over 6 months compared with placebo [10]. These are Level I data, though regulatory authorities have not approved testosterone for sarcopenia, partly because the TRAVERSE cardiovascular safety trial (N = 5,246) raised awareness of a small absolute increase in cardiovascular events (7.0% vs. 5.7% for placebo, HR 1.07) that complicates risk-benefit discussions in older men [11].

Off-Label Use 5: Male Osteoporosis and Bone Density Preservation

The T-Trials Bone sub-study (N = 211) used quantitative computed tomography and found that one year of testosterone increased estimated vertebral bone strength by 10.8% versus 2.4% with placebo [12]. Volumetric trabecular BMD at the spine rose by 6.4% in the testosterone group. These results are particularly relevant because testosterone's bone effects operate through two mechanisms: direct AR stimulation of osteoblasts and estradiol-mediated suppression of osteoclast activity after aromatization [3].

Evidence level is II. No RCT has been powered to detect fracture reduction with testosterone alone in men. The Endocrine Society's 2018 guideline on male osteoporosis recommends testosterone therapy as an adjunct in hypogonadal men who also receive bisphosphonates when T-scores fall below -2.5 [12]. For men with borderline BMD (T-score between -1.0 and -2.5) and confirmed low testosterone, testosterone replacement alone is considered a reasonable first step before adding antiresorptive agents.

Off-Label Use 6: Chronic Disease-Related Anemia

Testosterone stimulates erythropoiesis through EPO upregulation and direct stimulation of erythroid progenitor cells. The T-Trials Anemia sub-study reported that testosterone treatment corrected unexplained anemia (hemoglobin <12.7 g/dL) in 58.3% of hypogonadal men versus 22.2% on placebo [13]. For anemia of known cause, the correction rate was 52.9% versus 19.2%. These differences were statistically significant and clinically meaningful.

This is Level II evidence. No dedicated Phase III trial has tested testosterone enanthate as an anemia treatment. The practical challenge is that the same erythropoietic effect that corrects anemia can push hematocrit above 54% in eugonadal men, triggering polycythemia and increasing thromboembolic risk. The Endocrine Society recommends withholding testosterone if hematocrit exceeds 54% and resuming at a lower dose after therapeutic phlebotomy [1].

Off-Label Use 7: Depressive Symptoms in Hypogonadal Men

A 2019 meta-analysis of 27 RCTs (N = 1,890) in JAMA Psychiatry found that testosterone therapy reduced depressive symptoms with a standardized mean difference of 0.21 (95% CI 0.10 to 0.32), an effect most pronounced in men with baseline hypogonadism and mild-to-moderate depression [14]. The effect size was smaller than SSRIs (typically 0.3 to 0.4) but statistically significant.

Evidence level is II. The T-Trials Vitality component showed improvement in mood using the PHQ-9 depression screener, though the magnitude was modest (1.2-point difference on PHQ-9, P = 0.04) [9]. Testosterone is not a standalone antidepressant. The American Psychiatric Association does not include testosterone in its depression treatment guidelines. Clinical use is best reserved for men with both documented hypogonadism and treatment-resistant depression who are already on standard antidepressant therapy, as an augmentation strategy.

Off-Label Use 8: Cognitive Function and Neuroprotection

This application has the weakest evidence base. The T-Trials Cognitive Function Trial (N = 493) found no significant improvement in verbal memory or executive function at 12 months [15]. Small pilot RCTs (N = 10 to 44) have reported mixed results for spatial cognition and verbal fluency in hypogonadal men over 60 [15].

Preclinical data are more promising: testosterone reduces beta-amyloid accumulation in murine models, and androgen receptors are densely expressed in the hippocampus [2]. A 2020 Cochrane review concluded that "there is insufficient evidence to support or refute the use of testosterone for cognitive impairment or dementia" [15]. Evidence level is IV (expert opinion and preclinical data). Prescribing testosterone for cognitive protection alone is not supported by current clinical evidence.

Evidence-Level Summary Table

The hierarchy across these eight applications runs from strong to speculative. HSDD in women (Level I, meta-analysis of 36 RCTs), HIV-associated wasting (Level I, multiple RCTs), and gender-affirming therapy (Level I to II, large prospective cohorts plus guideline consensus) sit at the top. Sarcopenia (Level I to II), osteoporosis (Level II), anemia (Level II), and depression augmentation (Level II) occupy the middle tier. Cognitive neuroprotection (Level IV) remains investigational only [9][14][15].

Clinicians considering off-label testosterone enanthate should document the clinical rationale, obtain informed consent that specifies the off-label nature, monitor hematocrit and PSA per Endocrine Society guidelines, and reassess therapeutic response at 3 and 6 months. The TRAVERSE trial's cardiovascular signal (HR 1.07 for MACE) applies across all indications and should factor into every shared decision-making conversation [11].